Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

References

• Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:943–960.
   PubMed Web of Science ®Google Scholar
• Wrench D, Gribben JG. Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008;22:1051–1079, xi.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2010. Available from: http://www.cibmtr.org
   Google Scholar
• Alessandrino EP, Bernasconi P, Colombo A, . Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000;25:309–313.
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin JH, Churchill WH, . Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990;8:648–656.
   PubMed Web of Science ®Google Scholar
• Rubio C, Hill ME, Milan S, . Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997;75:1044–1048.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Appelbaum FR, Petersen FB, . High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993;11:1329–1335.
   PubMed Web of Science ®Google Scholar
• Wong R, Rondon G, Saliba RM, . Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003;31:1157–1163.
   PubMed Web of Science ®Google Scholar
• Benekli M, Smiley SL, Younis T, . Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008;41:613–619.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, . High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–813.
   PubMed Web of Science ®Google Scholar
• Nademanee A, O’Donnell MR, Snyder DS, . High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85:1381–1390.
   PubMed Web of Science ®Google Scholar
• Puig N, de la Rubia J, Remigia MJ, . Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47:1488–1494.
   PubMed Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Connors JM, . Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871–1879.
   PubMed Web of Science ®Google Scholar
• Todd NW, Peters WP, Ost AH, . Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:1264–1270.
   PubMed Web of Science ®Google Scholar
• Cao TM, Negrin RS, Stockerl-Goldstein KE, . Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6: 387–394.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Ager S, Mahendra P, Richards EM, . High-dose carmustine, etoposide and melphalan (“BEM”) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996;17:335–340.
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman EH, Lipshultz SE, . Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26: 3777–3784.
   PubMed Web of Science ®Google Scholar
• Durant JR, Norgard MJ, Murad TM, . Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 1979;90:191–194.
   PubMed Web of Science ®Google Scholar
• Jones RB, Matthes S, Shpall EJ, . Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993;85:640–647.
   PubMed Web of Science ®Google Scholar
• Krivoy N, Hoffer E, Lurie Y, . Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008;3:60–66.
   PubMedGoogle Scholar
• Kalaycioglu M, Kavuru M, Tuason L, . Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995;107:482–487.
   PubMed Web of Science ®Google Scholar
• Abushamaa AM, Sporn TA, Folz RJ. Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 2002;283:L336–L345.
   PubMed Web of Science ®Google Scholar
• Stahl W, Eisenbrand G. Comparative study on the influence of two 2-chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione-related enzymes in different organs of the rat. Free Radic Res Commun 1991;14:271–278.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23: 5235–5246.
   PubMed Web of Science ®Google Scholar
• Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172–1183.
   PubMed Web of Science ®Google Scholar
• Schulz C, Boeck S, Heinemann V, . UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009;20:867–879.
   PubMed Web of Science ®Google Scholar